- Home
- PHGE vs AIMD Comparison
PHGE vs AIMD Comparison
Compare PHGE & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- AIMD
- Stock Information
- Founded
- PHGE 2015
- AIMD 1984
- Country
- PHGE Israel
- AIMD United States
- Employees
- PHGE N/A
- AIMD N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- PHGE Health Care
- AIMD Health Care
- Exchange
- PHGE Nasdaq
- AIMD Nasdaq
- Market Cap
- PHGE 10.4M
- AIMD 11.9M
- IPO Year
- PHGE N/A
- AIMD N/A
- Fundamental
- Price
- PHGE $0.56
- AIMD $3.46
- Analyst Decision
- PHGE Strong Buy
- AIMD
- Analyst Count
- PHGE 1
- AIMD 0
- Target Price
- PHGE $15.00
- AIMD N/A
- AVG Volume (30 Days)
- PHGE 12.4M
- AIMD 7.2M
- Earning Date
- PHGE 08-13-2025
- AIMD 08-13-2025
- Dividend Yield
- PHGE N/A
- AIMD N/A
- EPS Growth
- PHGE N/A
- AIMD N/A
- EPS
- PHGE N/A
- AIMD N/A
- Revenue
- PHGE N/A
- AIMD $110,870.00
- Revenue This Year
- PHGE N/A
- AIMD N/A
- Revenue Next Year
- PHGE N/A
- AIMD N/A
- P/E Ratio
- PHGE N/A
- AIMD N/A
- Revenue Growth
- PHGE N/A
- AIMD 70.25
- 52 Week Low
- PHGE $0.34
- AIMD $2.00
- 52 Week High
- PHGE $1.90
- AIMD $5.00
- Technical
- Relative Strength Index (RSI)
- PHGE 57.85
- AIMD 60.77
- Support Level
- PHGE $0.48
- AIMD $3.05
- Resistance Level
- PHGE $0.59
- AIMD $3.58
- Average True Range (ATR)
- PHGE 0.07
- AIMD 0.40
- MACD
- PHGE 0.01
- AIMD 0.10
- Stochastic Oscillator
- PHGE 52.48
- AIMD 53.78
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.